March 18 Satellite Symposium | The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies

ACTIVITY TITLE

CME Symposium
The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies

ACTIVITY DATE

March 18, 2021 | 1:00 PM - 2:00 PM | Live Online at the Renal Physicians Association Annual Meeting | Eastern Time

This satellite symposium is approved by the RPA Education Committee; however, it is not part of the official RPA Annual Meeting as planned by the committee. 

PROGRAM OVERVIEW

Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs). These agents have shown promise in DKD, as demonstrated in recent clinical trial results, with phase III trial results recently announced and also ongoing. 

During this symposium, experts will discuss the pathophysiology of DKD and the role of MR overactivation in disease progression, as well as the interpretation of recent clinical trial data with novel MRAs in reducing cardio-renal risk in DKD patients.

HOW TO REGISTER

There is no registration fee for participating and receiving CE credit for this educational activity. You must, however, be registered to attend the Renal Physicians Association (RPA) Annual meeting. The RPA website and registration information can be found here

HOW TO CLAIM CE CREDIT

Please go to the Register tab to sign up and access the CE evaluation for this symposium. 

Target Audience

Healthcare professionals, including nephrologists, cardiologists, primary care clinicians (PCPs), pharmacists, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify T2DM patients at risk for kidney disease or kidney disease progression. 
  • Summarize the mechanisms of action of emerging DKD treatments.
  • Interpret the latest clinical trial data with emerging treatment options for DKD.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
03/18/2021
Course expires: 
04/30/2021
Rating: 
0

George L. Bakris, MD (Chair)
Professor of Medicine
Director, Am. Heart Assoc Comprehensive Hypertension CenterThe University of Chicago Medicine
Chicago, IL

Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University School of Medicine and VA Medical Center
Indianapolis, IN

Gerasimos Filippatos, MD, FESC, FHFA, FHFSA(h)
Professor of Cardiology
National and Kapodistrian University of Athens School of Medicine
Athens, Greece

EDUCATIONAL SUPPORT

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

JOINT ACCREDITATION STATEMENT

 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING PHARMACY EDUCATION

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an knowledge-based activity. Universal Activity Numbers (UAN) JA4008162-9999-21-2623-L01-P.

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor within 4-6 weeks. Pharmacists have up to thirty (30) days from the live event to complete the evaluation and claim credit.

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. 

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Dr. Bakris discloses the following:  

Consulting Fees: Merck, Vifor, Ionis,  Alynalam, Bayer,  Novo Nordisk
Contracted Research: InRegen, KBP Biosciences

Dr. Agarwal discloses the following: 

Salary: Indiana University, VA
Royalty: Up To Date
Consulting Fees: Akebia Therapeutics Inc; Astrazeneca AB; Astrazeneca Pharmaceuticals LP; Bayer Healthcare Pharmaceuticals Inc.; Boehringer Ingelheim B.V.; Boehringer Ingelheim International GMBH
Boehringer Ingelheim Pharma GbmH & Co KG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Ironwood Pharmaceuticals, Inc; Janssen Research & Development, LLC; Relypsa, Inc. Sanofi Vifor Fresenius Medical Care Renal Pharma Ltd.; Merck & Co; Lexicon; Reata

Dr. Filippatos discloses the following: 

Salary: University of Athens
Speakers' Bureaus: Boehringer Ingelheim, Bayer
Committee Member: BI, Bayer, Amgen, Servier, Medtronic

Planners and Managers

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

HOW TO CLAIM CREDIT

**IMPORTANT NOTE**

You are registering to access the CE evaluation for attending a March 18 satellite symposium at the RPA Annual Meeting. You must be registered for the RPA Annual Meeting to view the symposium. 

How to Claim Your Credits:
Once you have completed viewing the symposium and would like to claim credit you must return and login to this website. Please note this is a separate site from www.cardiometabolichealth.org and from the RPA Annual Meeting. To access the evaluation, please follow the steps below:

  1. Click here to register or login now.
  2. Once you are logged into your account, return here to the Register/Login tab and click on the blue "Take Course" button to access the evaluation survey. 
  3. Please complete the evaluation and you will then be able to print your CE certificate. Thank you.

The evaluation link will be accessible on the meeting day (March 18). For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no registration fee for participating and receiving CME/CE credit for this educational activity. You must, however, be registered to attend the Renal Physicians Association (RPA) Annual meeting. The RPA website and registration information can be found here

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

**IMPORTANT NOTE**

You are registering to access the CE evaluation for attending a March 18 satellite symposium at the RPA Annual Meeting. You must be registered for the RPA Annual Meeting to view the symposium. 

How to Claim Your Credits:
Once you have completed viewing the symposium and would like to claim credit you must return and login to this website. Please note this is a separate site from www.cardiometabolichealth.org and from the RPA Annual Meeting. To access the evaluation, please follow the steps below:

  1. Click here to register or login now.
  2. Once you are logged into your account, return here to the Register/Login tab and click on the blue "Take Course" button to access the evaluation survey. 
  3. Please complete the evaluation and you will then be able to print your CE certificate. Thank you.

The evaluation link will be accessible on the meeting day (March 18). For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org